What is claimed is:

1. An anti-CD200 antibody, or a CD200-binding fragment thereof, for use in treating a human afflicted with a cancer that is resistant to an anti-CD20 antibody therapy.

2. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to claim 1, wherein the cancer is a chronic lymphocytic leukemia (CLL) comprising CLL cells having reduced expression of CD20, relative to the expression of CD20 by normal cells of the same histological type as the cells from which the cancer cells are derived.

3. The anti-CD200 antibody, or a CD200-binding fragment thereof, for use according to claim 2, wherein the CLL comprises CLL cells that express CD5.

4. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to claim 1, wherein the cancer is a liquid tumor.

5. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to claim 4, wherein the liquid tumor is a chronic lymphocytic leukemia or multiple myeloma.

6. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 2, 3, or 5, wherein the chronic lymphocytic leukemia is a B cell chronic lymphocytic leukemia.

7. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-6, wherein the anti-CD20 antibody therapy comprises rituximab, ofatumumab, TRU-015, veltuzumab, ocrelizumab, or AME-133v.

8. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-6, wherein the anti-CD20 antibody therapy comprises an anti-CD20 antibody, or CD20-binding fragment thereof, conjugated to a toxin.

9. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to claim 8, wherein the toxin is selected from the group consisting of a small molecule drug, a toxic polypeptide, a bacterial toxin, a fungal toxin, a plant toxin, or a radioactive agent.

10. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is a bispecific antibody comprising a first antigen combining site that binds to CD200 and a second antigen combining site that binds to CD20.

11. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, inhibits the interaction between CD200 and CD200R.

12. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, contains one of the following paired set of CDRs:

(i) a heavy chain CDR1 (HCDR1) comprising the amino acid sequence: GFTFSGFAMS (SEQ ID NO:4); a heavy chain CDR2 (HCDR2) comprising the amino acid sequence: SISSGGTTYYLDSVKG (SEQ ID NO:5); a heavy chain CDR3 (HCDR3) comprising the amino acid sequence: GNYYSGTSYDY (SEQ ID NO:6); a light chain CDR1 (LCDR1) comprising the amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:7); a light chain CDR2 (LCDR2) comprising the amino acid sequence: RASNLES (SEQ ID NO:8); and a light chain CDR3 (LCDR3) comprising the amino acid sequence: QQSNEDPRT (SEQ ID NO:9);

(ii) a HCDR1 comprising the amino acid sequence: GFNIKDYYMH (SEQ ID NO:10); a HCDR2 comprising the amino acid sequence: WIDPENGDTKYAPKFQG (SEQ ID NO:11); a HCDR3 comprising the amino acid sequence: KNYYVSNYNFFDV (SEQ ID NO:12); a LCDR1 comprising the amino acid sequence: SASSSVRYMY (SEQ ID NO:13); a LCDR2 comprising the amino acid sequence: DTSKLAS (SEQ ID NO:14); and a LCDR3 comprising the amino acid sequence: FQGSGYPLT (SEQ ID NO:15);

(iii) a HCDR1 comprising the amino acid sequence: GFNIKDYYIH (SEQ ID NO:16); a HCDR2 comprising the amino acid sequence: WIDPEIGATKYVPKFQG (SEQ ID NO:17); a HCDR3 comprising the amino acid sequence: LYGNYDRYYAMDY (SEQ ID NO:18); a LCDR1 comprising the amino acid sequence: KASQNVRTAVA (SEQ ID NO:19); a LCDR2 comprising the amino acid sequence: LASNRHT (SEQ ID NO:20); and a LCDR3 comprising the amino acid sequence: LQHWNYPLT (SEQ ID NO:21);

(iv) a HCDR1 comprising the amino acid sequence: GYSFTDYIIL (SEQ ID NO:22); a HCDR2 comprising the amino acid sequence: HIDPYYGSSNYNLKFKG (SEQ ID NO:23); a HCDR3 comprising the amino acid sequence: SKRDYFDY (SEQ ID NO:24); a LCDR1 comprising the amino acid sequence: KASQDINSYLS (SEQ ID NO:25); a LCDR2 comprising the amino acid sequence: RANRLVD (SEQ ID NO:26); and a LCDR3 comprising the amino acid sequence: LQYDEFPYT (SEQ ID NO:27);

(v) a HCDR1 comprising the amino acid sequence: GYTFTEYTMH (SEQ ID NO:28); a HCDR2 comprising the amino acid sequence: GVNPNNGGALYNQKFKG (SEQ ID NO:29); a HCDR3 comprising the amino acid sequence: RSNYRYDDAMDY (SEQ ID NO:30); a LCDR1 comprising the amino acid sequence: KSSQSLLDIDEKTYLN (SEQ ID NO:31); a LCDR2 comprising the amino acid sequence: LVSKLDS (SEQ ID NO:32); and a LCDR3 comprising the amino acid sequence: WQGTHFPQT (SEQ ID NO:33); or

(vi) a HCDR1 comprising the amino acid sequence: AFNIKDHYMH (SEQ ID NO:34); a HCDR2 comprising the amino acid sequence: WIDPESGDTEYAPKFQG (SEQ ID NO:35); a HCDR3 comprising the amino acid sequence: FNGYQALDQ (SEQ ID NO:36); a LCDR1 comprising the amino acid sequence: TASSSVSSSYLH (SEQ ID NO:37); a LCDR2 comprising the amino acid sequence: STSNLAS (SEQ ID NO:38); and a LCDR3 comprising the amino acid sequence: RQYHRSPPIFT (SEQ ID NO:39).

13. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is murine, chimeric, humanized, or fully human.

14. The anti-CD200 antibody, or CD200-binding fragment thereof, for use according to any one of claims 1-9, wherein the CD200-binding fragment is selected from the group consisting of

~~a Fab fragment, a F(ab')$_2$ fragment, a Fab' fragment, an scFv fragment, a minibody, a diabody, or a triabody.~~

~~15.~~ 1. Use of an anti-CD200 antibody, or a CD200-binding fragment thereof, in the manufacture of a medicament for treating a human afflicted which a cancer that is resistant to an anti-CD20 antibody therapy.

~~16.~~ 2. The use according to claim ~~15~~ 1, wherein the cancer is a chronic lymphocytic leukemia (CLL) comprising CLL cells having reduced expression of CD20, relative to the expression of CD20 by normal cells of the same histological type as the cells from which the cancer cells are derived.

~~17.~~ 3. The use according to claim ~~16~~ 2, wherein the CLL comprises CLL cells that express CD5.

~~18.~~ 4. The use according to claim ~~15~~ 1, the cancer is a liquid tumor.

~~19.~~ 5. The use according to claim ~~18~~ 4, wherein the liquid tumor is a chronic lymphocytic leukemia or multiple myeloma.

~~20.~~ 6. The use according to any one of claims ~~16~~ 2, ~~17~~ 3, or ~~19~~ 5, wherein the chronic lymphocytic leukemia is a B cell chronic lymphocytic leukemia.

~~21.~~ 7. The use according to any one of claims ~~15-20~~ 1-6, wherein the anti-CD20 antibody therapy comprises rituximab, ofatumumab, TRU-015, veltuzumab, ocrelizumab, or AME-133v.

~~22.~~ 8. The use according to any one of claims ~~15-20~~ 1-6, wherein the anti-CD20 antibody therapy comprises an anti-CD20 antibody, or CD20-binding fragment thereof, conjugated to a toxin.

~~23.~~ 9. The use according to claim ~~22~~ 8, wherein the toxin is selected from the group consisting of a small molecule drug, a toxic polypeptide, a bacterial toxin, a fungal toxin, a plant toxin, or a radioactive agent.

~~24.~~ 10. The use according to any one of claims ~~15-23~~ 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is a bispecific antibody comprising a first antigen combining site that binds to CD200 and a second antigen combining site that binds to CD20.

~~25.~~ 11. The use according to any one of claims ~~15-23~~ 1-9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, inhibits the interaction between CD200 and CD200R.

~~26.~~ 12. The use according to any one of claims ~~15~~ 1 to ~~23~~ 9, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, contains one of the following paired set of CDRs:

(i) a heavy chain CDR1 (HCDR1) comprising the amino acid sequence: GFTFSGFAMS (SEQ ID NO:4); a heavy chain CDR2 (HCDR2) comprising the amino acid

sequence: SISSGGTTYYLDSVKG (SEQ ID NO:5); a heavy chain CDR3 (HCDR3) comprising the amino acid sequence: GNYYSGTSYDY (SEQ ID NO:6); a light chain CDR1 (LCDR1) comprising the amino acid sequence: RASESVDSYGNSFMH (SEQ ID NO:7); a light chain CDR2 (LCDR2) comprising the amino acid sequence: RASNLES (SEQ ID NO:8); and a light chain CDR3 (LCDR3) comprising the amino acid sequence: QQSNEDPRT (SEQ ID NO:9);

(ii) a HCDR1 comprising the amino acid sequence: GFNIKDYYMH (SEQ ID NO:10); a HCDR2 comprising the amino acid sequence: WIDPENGDTKYAPKFQG (SEQ ID NO:11); a HCDR3 comprising the amino acid sequence: KNYYVSNYNFFDV (SEQ ID NO:12); a LCDR1 comprising the amino acid sequence: SASSSVRYMY (SEQ ID NO:13); a LCDR2 comprising the amino acid sequence: DTSKLAS (SEQ ID NO:14); and a LCDR3 comprising the amino acid sequence: FQGSGYPLT (SEQ ID NO:15);

(iii) a HCDR1 comprising the amino acid sequence: GFNIKDYYIH (SEQ ID NO:16); a HCDR2 comprising the amino acid sequence: WIDPEIGATKYVPKFQG (SEQ ID NO:17); a HCDR3 comprising the amino acid sequence: LYGNYDRYYAMDY (SEQ ID NO:18); a LCDR1 comprising the amino acid sequence: KASQNVRTAVA (SEQ ID NO:19); a LCDR2 comprising the amino acid sequence: LASNRHT (SEQ ID NO:20); and a LCDR3 comprising the amino acid sequence: LQHWNYPLT (SEQ ID NO:21);

(iv) a HCDR1 comprising the amino acid sequence: GYSFTDYIIL (SEQ ID NO:22); a HCDR2 comprising the amino acid sequence: HIDPYYGSSNYNLKFKG (SEQ ID NO:23); a HCDR3 comprising the amino acid sequence: SKRDYFDY (SEQ ID NO:24); a LCDR1 comprising the amino acid sequence: KASQDINSYLS (SEQ ID NO:25); a LCDR2 comprising the amino acid sequence: RANRLVD (SEQ ID NO:26); and a LCDR3 comprising the amino acid sequence: LQYDEFPYT (SEQ ID NO:27);

(v) a HCDR1 comprising the amino acid sequence: GYTFTEYTMH (SEQ ID NO:28); a HCDR2 comprising the amino acid sequence: GVNPNNGGALYNQKFKG (SEQ ID NO:29); a HCDR3 comprising the amino acid sequence: RSNYRYDDAMDY (SEQ ID NO:30); a LCDR1 comprising the amino acid sequence: KSSQSLLDIDEKTYLN (SEQ ID NO:31); a LCDR2 comprising the amino acid sequence: LVSKLDS (SEQ ID NO:32); and a LCDR3 comprising the amino acid sequence: WQGTHFPQT (SEQ ID NO:33); or

(vi) a HCDR1 comprising the amino acid sequence: AFNIKDHYMH (SEQ ID NO:34); a HCDR2 comprising the amino acid sequence: WIDPESGDTEYAPKFQG (SEQ ID NO:35); a HCDR3 comprising the amino acid sequence: FNGYQALDQ (SEQ ID NO:36); a LCDR1 comprising the amino acid sequence: TASSSVSSSYLH (SEQ ID NO:37);

a LCDR2 comprising the amino acid sequence: STSNLAS (SEQ ID NO:38); and a LCDR3 comprising the amino acid sequence: RQYHRSPPIFT (SEQ ID NO:39).

~~27.~~ 13. The use according to any one of claims ~~15~~ 1 to ~~24~~ 10, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is murine, chimeric, humanized, or fully human.

~~28.~~ 14. The use according to any one of claims ~~15~~ 1 to ~~24~~ 10, wherein the CD200-binding fragment is selected from the group consisting of a Fab fragment, a $F(ab')_2$ fragment, a Fab' fragment, an scFv fragment, a minibody, a diabody, or a triabody.